Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cellular Oncology is Scopus-indexed (Q1, CiteScore 8.6), WoS SCIE. Published by Springer Science and Business Media B.V..
Checked against the index lists dated .
ISSN 2211-3428Verify ISSN ↗2211-3436Verify ISSN ↗
Publisher: Springer Science and Business Media B.V.
Cost to publish: About US$4,390 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 70 / 428 | 83rd | Q1 |
| Molecular Medicine | 43 / 179 | 76th | Q1 |
| Cancer Research | 60 / 233 | 74th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2011–present, best quartile Q1, CiteScore 8.6.
Cellular Oncology is Q1 in Oncology (rank 70 of 428), Q1 in Molecular Medicine (rank 43 of 179) and Q2 in Cancer Research (rank 60 of 233), by CiteScore 2025.
Cellular Oncology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 8.6, which places it in quartile Q1 at the 83rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 1.561, quartile Q1, with an H-index of 68.
The publisher lists an article processing charge of about US$4,390 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cellular Oncology is published by Springer Science and Business Media B.V. Its print ISSN is 2211-3428 and its online ISSN is 2211-3436.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal per Scopus.
Cellular Oncology has an h-index of 76 and a 2-year mean of 4.3 citations per paper (OpenAlex). Its Scopus CiteScore is 8.6, quartile Q1. On 2-year citations it ranks #74 of 424 Scopus journals in Oncology.
Cellular Oncology published 105 papers in 2025; its busiest recent year was 2023 with 147. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2026), authors are most often from China (82.9%), United States (2.6%) and Germany (2.5%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 16 retracted papers are recorded (12.1 per 1,000 papers). The Problematic Paper Screener flags 2 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.